Search the Newsreel

DarioHealth (NASDAQ:DRIO) Price Target Lowered to $8.00 at TD Cowen

TD Cowen has reduced its price target for DarioHealth (NASDAQ:DRIO) to $8.00 from $11.00, maintaining a "hold" rating, suggesting a potential upside of 3.76% from its current stock price. This adjustment comes despite DarioHealth reporting a narrower-than-expected loss in its latest quarter, though revenue …

DarioHealth Corp. Q2 2026 Earnings Call Summary

DarioHealth Corp. Q2 2026 Earnings Call Summary - Moby Strategic Evolution and Performance Drivers Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here. …

DarioHealth Reports Second Quarter 2026 Financial Results

DarioHealth (NASDAQ: DRIO) announced its Q2 2026 financial results, reporting revenue of $5.2 million and a gross margin increase to 62%. The company saw an 11% quarter-over-quarter and 30% year-over-year decrease in operating loss, alongside a 21% year-over-year decline in operating expenses, indicating improved …

DarioHealth (NASDAQ:DRIO) Issues Quarterly Earnings Results, Beats Estimates By $0.37 EPS

DarioHealth Q2 Earnings Call Highlights

Key Points Interested in DarioHealth Corp.? Here are five stocks we like better. Q2 revenue fell to $5.2 million as DarioHealth continued moving away from pharmaceutical services toward recurring B2B2C revenue, but gross margin improved to 62% and net loss narrowed to $7.9 million. …

Earnings call transcript: DarioHealth tops q2 2026 EPS forecast, misses revenue

DarioHealth (DRIO) reported a narrower-than-expected loss in Q2 2026, beating EPS forecasts by 32% with adjusted earnings of negative $0.85 per share, but missed revenue estimates at $5.18 million. The company's stock rose 4.93% after the announcement, driven by improved gross margins (62%) and …

DarioHealth earnings beat by $0.40, revenue fell short of estimates

DarioHealth Corp. (DRIO) Reports Q2 Loss, Lags Revenue Estimates

DarioHealth Corp. 2Q 2026: Revenue $5.18M, Net loss $7.92M — 10-Q Summary

DarioHealth Corp. reported a Q2 2026 revenue of $5.18 million, a slight decrease from the previous year, but significantly improved its net loss to $7.92 million from $18.56 million in Q2 2025. The company saw a shift towards B2B revenue, now comprising 75% of …

DARIOHEALTH Q2 2026 Earnings Preview: Recent $DRIO Insider Trading, Hedge Fund Activity, and More

DarioHealth Corp expected to post a loss of $1.21 a share - Earnings Preview

DarioHealth Corp is anticipated to report an upcoming earnings loss. Analysts predict the company will post a loss of $1.21 per share. This information is based on an earnings preview from Refinitiv.

Digital Health Provider Launches Women's Health & Sleep Solutions

DarioHealth Corp. (DRIO:NASDAQ) has introduced new "Dario Women" and "Dario Sleep" programs, expanding its cardiometabolic platform to address women's health during perimenopause and menopause, and obstructive sleep apnea. These additions cater to the growing demand from large employers and health plans for integrated digital …

About 2.5× Higher Costs for Untreated Sleep Apnea; Dario Launches Care

DarioHealth (NASDAQ: DRIO) has launched two new provider-backed programs, Dario Women™ and Dario Sleep™, expanding its AI-enabled cardiometabolic platform to address women's health and obstructive sleep apnea (OSA). These programs integrate AI, human coaching, and licensed healthcare providers, aiming for rollout to clients in …

DarioHealth (DRIO) Projected to Release Quarterly Earnings on Tuesday

Dario Expands Provider-Backed Cardiometabolic Platform with New Women's Health and Sleep Solutions Aligning with Client Demand – Company Announcement - FT.com

DarioHealth Corp. has expanded its cardiometabolic platform by introducing Dario Women™ and Dario Sleep™ solutions to address client demand for multi-condition offerings. These new programs integrate AI-powered engagement, behavioral coaching, and access to licensed healthcare providers to improve outcomes for women's health concerns like …

DarioHealth to Report Second Quarter 2026 Results on Tuesday, August 11, 2026

DarioHealth Corp. (Nasdaq: DRIO) announced it will release its second-quarter 2026 financial results on Tuesday, August 11, 2026, before market open. The AI-powered healthcare technology company will host a conference call and webcast at 8:30 a.m. Eastern Time, featuring its CEO, COO, and CFO …

DarioHealth launches women’s health and sleep programs By Investing.com

DarioHealth Corp. (NASDAQ:DRIO) has announced the launch of two new programs, Dario Women and Dario Sleep, expanding its cardiometabolic healthcare platform. These programs integrate digital engagement, behavioral coaching, and clinical care, targeting women's health during perimenopause and menopause, and obstructive sleep apnea. Both are …

Digital Health Firm Launches Integrated GLP-1 Program

DarioHealth Corp. (DRIO:NASDAQ) has launched an Integrated GLP-1 Program, combining its digital platform with Beluga Health's clinical oversight to offer end-to-end support for GLP-1 therapies, including evaluation, prescribing, and chronic care management. This program aims to address the rapidly growing GLP-1 market, targeting employers …

DarioHealth to release Q2 2026 earnings and host conference call on August 11 before market opens

DarioHealth Corp., an AI-driven healthcare tech company, will release its Q2 2026 financial results on August 11 at 8:30 a.m. ET, prior to market opening. Following the announcement, the company will host a conference call and webcast with its CEO, COO, and CFO to …

DarioHealth Corp (DRIO) Institutional Confidence

This article from TradingKey provides an overview of the institutional confidence in DarioHealth Corp (DRIO). It lists key institutional shareholders, their shareholdings, and the percentage change in their positions. The company's stock is currently trading at $7.270, up 0.97%.

DarioHealth launches integrated GLP-1 program with clinical care

DarioHealth Corp. has launched an Integrated GLP-1 Program, developed in collaboration with Beluga Health, which integrates licensed provider evaluations, FDA-approved GLP-1 medication prescribing, and clinical oversight with Dario's existing chronic care platform. The program aims to address the growing demand for GLP-1 treatments, with …

DRIO|DarioHealth Corp|Price:7.100|Chg%:-0.395

This article provides a comprehensive stock analysis of DarioHealth Corp (DRIO), highlighting its relatively healthy fundamentals, good growth potential, and fair valuation within the Healthcare Equipment & Supplies industry. Despite recent stock market performance, the company's weak fundamentals and technicals do not fully support …

Form 4 DarioHealth Corp For: 28 July By Investing.com

The article reports on a Form 4 filing for DarioHealth Corp (DRIO) pertaining to July 28. It is primarily a placeholder for financial regulatory information, with no specific details of the Form 4 included, indicating readers should refer to the actual filing for details. …

DarioHealth Corp. (DRIO) director buys 14,430 shares at $6.93

DarioHealth Corp. director Dennis Matheis purchased 14,430 shares of common stock at $6.93 per share on July 23, 2026, as part of a Securities Purchase Agreement. This purchase increased his direct common stock holdings to 43,026 shares. The transaction followed an earlier automatic conversion …

DarioHealth Corp (DRIO) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for DarioHealth Corp (DRIO), focusing on its volatility, financial risk, and investment risk. The company has a current risk assessment score of 1.97, ranking it 164 out of 199 in the Healthcare Equipment & Supplies industry. Key metrics …

DarioHealth Corp (DRIO) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of DarioHealth Corp (DRIO), detailing its support and resistance levels, indicator signals, and moving averages. While the stock's current price momentum score is 4.75, making it suitable for range-bound swing trading, its overall signal based on technical indicators …

DarioHealth Corp (DRIO) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of DarioHealth Corp (DRIO), identifying major individual and institutional holders. It provides a breakdown of shareholder types, institutional shareholding over several quarters, and recent changes in holdings by key shareholders. The data indicates proportions held by various entities …

DarioHealth Corp (DRIO) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of DarioHealth Corp's (DRIO) dividend history and stock split events. It states that DRIO has distributed 0.00 USD in dividends over the past 5 years, with no recent dividend data available. The company had a stock split event on …

DarioHealth Corp

DarioHealth Corp. (DRIO) is a digital therapeutics company offering personalized interventions for managing various chronic conditions like diabetes and hypertension. The article provides an overview of the company's profile, including its platform, products like the Dario Blood Glucose Monitoring Starter Kit, and details about …

DarioHealth Corp (DRIO) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of DarioHealth Corp (DRIO), noting its current valuation score of 8.21, which ranks 109th in the Healthcare Equipment & Supplies industry. It highlights the company's P/E ratio and mentions that relevant data for P/B, P/S, and P/CF ratios …

Form 424B5 DarioHealth Corp For: 22 July By Investing.com

This article announces the filing of Form 424B5 by DarioHealth Corp for July 22, 2026. The content is brief, primarily acting as a notification of the SEC filing. It also lists the company's stock symbol DRIO and its performance for the day.

DarioHealth Raises $23.5 Million in Registered Direct Offering; Taps A.G.P. as Placement Agent

DarioHealth announced a registered direct offering to raise approximately $23.5 million through the sale of common shares and pre-funded warrants, with a target closing date of July 23, 2026. The company appointed A.G.P./Alliance Global Partners as its sole placement agent for the offering. Additionally, …

DarioHealth Plans About $23.5M Stock Sale for Acquisitions

DarioHealth (NASDAQ: DRIO) announced a registered direct offering of 3,454,559 shares at $6.80 each, expected to raise approximately $23.5 million in gross proceeds. The offering, priced at-the-market under Nasdaq rules, includes participation from existing institutional investors, a new global investor, and a board member. …